Iantrek is excited to announce the closing of their $23M Series B financing. The oversubscribed financing was led by a couple of institutional investors and the newly raised capital will be used to initiate clinical introduction and post-marketing studies of Iantrek’s MIGS devices. Iantrek further announced the appointment of Dr. Sean Ianchulev, the company’s founder and Chairman, as the company’s CEO.
Iantrek has also strengthened its ophthalmic technology leadership with the appointment of Jason Cha (ex-Ivantis) as the Vice President of Sales and Marketing and Ginger Clasby (ex-Transcend Medical) as the Head of Clinical Operations and Regulatory. Read the full article..
